JNJ-42165279
Phase 2Small molecule
Johnson & JohnsonJNJ-42165279 is one of 136 small molecule programs targeting Social Anxiety Disorder. It is currently in Phase 2.
4
Indications
9
Total Trials
0
Active Trials
135
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaPhase 3
Psilocybin
COMPASS PathwaysPhase 3
Fetzima
AbbViePhase 3
Bupropion XL
GSKPhase 3
Seltorexant
Johnson & JohnsonPhase 3
Seroquel IR
OtsukaPhase 3
SR58611A
SanofiPhase 3
Aticaprant
Johnson & JohnsonPhase 3
CYB003
CCybin IRL Limited
Phase 3
Minocyclin
UUniversity of Southern California
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tics2 trials
Social Anxiety Disorder1 trial
Major Depressive Disorder1 trial
IgAN1 trial
3 more indications
Elderly Participants1 trial
Anxiety Disorder1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JNJ-42165279. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company